Document Detail

Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.
MedLine Citation:
PMID:  23143437     Owner:  NLM     Status:  Publisher    
Tuberculosis (TB) has scourged humankind for millennia, and latent infection affects nearly one-third of today's world population. The emergence of multidrug-resistant (MDR)-TB is a major global threat and reflects treatment failure of drug-sensitive disease. MDR-TB management is a burden for patients and society; success rates are unacceptably low with prolonged treatment duration. Mycobacterium tuberculosis (Mtb) possesses the ability to transform into a dormant state in which it can persist in the face of antimicrobial treatment and host defense. This sub-population of persisters is largely responsible for lengthy and difficult treatment. Targeting persistent bacilli could eventually improve the treatment success rate (currently 50-65 %) and shorten duration of treatment. A subset of therapies in the pipeline, termed therapeutic vaccines, use the host immune response to attack Mtb. The historical occurrence of an exacerbated host response has resulted in a negative perception of therapeutic vaccines. Thus, a renewed concept of immunotherapy is needed. We review current perspectives of immunotherapy in MDR-TB based on the knowledge of TB immunology and briefly discuss the profiles of several therapeutic vaccine products.
Satria A Prabowo; Matthias I Gröschel; Ed D L Schmidt; Alena Skrahina; Traian Mihaescu; Serap Hastürk; Rotislav Mitrofanov; Edita Pimkina; Ildikó Visontai; Bouke de Jong; John L Stanford; Père-Joan Cardona; Stefan H E Kaufmann; Tjip S van der Werf
Related Documents :
24505407 - Evidence for a role for interleukin-17, th17 cells and iron homeostasis in protective i...
22930707 - Delivering influenza vaccine to high-risk adults: subspecialty physician practices.
23798697 - Economic considerations for the eradication endgame.
25015137 - Safety of pertussis vaccination in pregnant women in uk: observational study.
21906647 - Trivalent and quadrivalent mf59-adjuvanted influenza vaccine in young children: a dose-...
21817957 - Response to primary and booster vaccination with 10-valent pneumococcal nontypeable hae...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-10
Journal Detail:
Title:  Medical microbiology and immunology     Volume:  -     ISSN:  1432-1831     ISO Abbreviation:  Med. Microbiol. Immunol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0314524     Medline TA:  Med Microbiol Immunol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Retroperitoneal duplication cyst with a fistulous tract to the vagina: a case report.
Next Document:  Subjective quality of vision before and after cataract surgery.